Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats

Neuroscience

Volumn 95, Issue 4, 1999, Pages 1049-1059

  Lorenc Koci, E ^a   Smialowska M ^a   Antkiewicz Michaluk, L ^a   Golembiowska, K ^a   Bajkowska, M ^a   Wolfarth, S ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1,2,3,4 Tetrahydroisoquinoline; Endogenous toxins; Muscle rigidity; Parkinson's disease

Indexed keywords

TETRAHYDROISOQUINOLINE; TYROSINE 3 MONOOXYGENASE; 1,2,3,4-TETRAHYDROISOQUINOLINE; DOPAMINE; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; ELECTROMYOGRAM; GASTROCNEMIUS MUSCLE; IMMUNOCYTOCHEMISTRY; MALE; MICRODIALYSIS; MUSCLE RIGIDITY; MUSCLE TONE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; ANIMAL; DRUG EFFECT; ELECTROMYOGRAPHY; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; TIME; WISTAR RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; ELECTROMYOGRAPHY; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; MALE; MICRODIALYSIS; MUSCLE TONUS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TETRAHYDROISOQUINOLINES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 0033631519     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00511-4     Document Type: Article

References (67)

1. Antkiewicz-Michaluk L., Romanska I., Michaluk J. The role of central dopamine system in the mechanism of action of tetrahydroisoquinoline. Naunyn-Schmiedeberg's Arch. Pharmac. 358:(Suppl. 1):1998;R100.
2. Arya D.K. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br. J. Psychiat. 165:1994;728-733.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J. neurol. Sci. 20:1973;415-455.
4. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80:1983;4546-4550.
5. Butcher S.P., Fairbrother I.S., Kelly J.S., Gordon W.A. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 55:1990;981-988.
6. Collins M.A., Neafsey E.J., Cheng B.Y., Hurley-Gius K., Ung-Chhun N.A., Pronger D.A., Christensen M.A., Hurley-Gius D. Endogenous N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-β-carbolines as potential causative factors in Parkinson's disease. Adv. Neurol. 45:1986;179-182.
7. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr. 38:1960;1236-1239.
8. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normal and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. neurol. Sci. 14:1971;427-455.
9. Forno L. S. (1982) Pathology of Parkinson's disease. In Movement Disorders (eds Marsden D. and Fahn S.), pp. 25-40. Butterworth, London.
10. Fukuda T. 2-Methyl-1,2,3,4-tetrahydroisoquinoline does dependently reduce the number of tyrosine hydroxylase-immunoreactive cells in the substantia nigra and locus ceruleus of C57BL/6J mice. Brain Res. 639:1994;325-328.
11. Hamilton M.S., Opler L.A. Akathisia, sucidality and fluoxetine. J. clin. Psychiat. 53:1992;401-406.
12. Hirata Y., Sugimura H., Takei H., Nagatsu T. The effects of pyridinium salts, structurally related compounds of 1-methyl-4-phenylpyridinium ion (MPP+), on tyrosine hydroxylation in rat striatal tissue slices. Brain Res. 397:1986;341-344.
13. Hornykiewicz O. (1982) Brain neurotransmitter changes in Parkinson's disease. In Movement Disorders (eds Marsden D. and Fahn S.), pp. 41-58. Butterworth, London.
14. Hornykiewicz O. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease - a critical analysis of the neurochemical evidence. Prog. Neuropsychopharmac. biol. Psychiat. 13:1989;319-328.
15. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrosriatal dopamine system: possible neurochemical mechanism. Adv. Neurol. 60:1993;140-147.
16. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 51:(Suppl. 2):1998;S2-S9.
17. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1986;19-34.
18. Hornykiewicz O., Pifl C., Kish S. J., Shannak K. and Schingnitz G. (1989) Biochemical changes in idiopathic Parkinson's disease, ageing, and MPTP Parkinsonism: similarities and differences. In Parkinsonism and Ageing (ed. Calne D. B.), pp. 57-67. Raven, New York.
19. Imperato A., Di Chiara G. Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J. Neurosci. 4:1984;966-977.
20. Johnson E.A., Wu E.Y., Rollema H., Booth R.G., Trevor A.J., Costagnoli N. 1-Methyl-4-phenylpyridinium (MPP+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake. Eur. J. Pharmac. 166:1989;65-74.
21. Kato T., Dong B., Cabbat F.S., Duvoisin R.C. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem. 46:1986;1277-1282.
22. Kikuchi K., Nagatsu Y., Makino Y., Mashino T., Ohta S., Hirobe M. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug. Metab. Dispos. 19:1990;257-262.
23. Kish S.J., Shannak K., Hornykiewicz P. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl. J. Med. 318:1988;876-880.
24. Kohno M., Ohta S., Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem. biophys. Res. Commun. 140:1986;448-454.
25. Kopin I.J. Toxins and Parkinson's disease: MPTP Parkinsonism in humans and animals. Adv. Neurol. 45:1986;137-144.
26. Korsgaard J., Gerlach E., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur. J. Pharmac. 118:1985;245-252.
27. Langston J.W. MPTP: insight into the etiology of Parkinson's disease. Eur. Neurol. 26:(Suppl. 1):1987;2-10.
28. Langston J.W., Ballard P., Tetrud J.W., Irvin I. Chronic parkinsonism in human due to a product of meperidine-analog synthesis. Science. 219:1983;976-980.
29. Lee R.G. Pathophysiology of rigidity and akinesia in Parkinson's disease. Eur. Neurol. 29:(Suppl. 1):1989;13-18.
30. Leonard B.E., Faherty C. SSRIs and movement disorders: is serotonin the culprit? Human Psychopharmac. 11:1996;S75-S82.
31. Lorenc-Koci E., Ossowska K., Wardas J., Wolfarth S. Does reserpine induce parkinsonian rigidity? J. neural Transm. (P-D Sect.). 9:1995;211-223.
32. Lorenc-Koci E., Wolfarth S., Ossowska K. Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Expl Brain Res. 109:1996;268-276.
33. Makino Y., Ohta S., Tachikawa O., Hirobe M. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson's disease. Life Sci. 43:1988;373-378.
34. Maruyama W., Nakahara D., Dostert P., Takahashi A., Naoi M. Naturally-occurring isoquinolines perturb monoamine metabolism in the brain: studied by in vivo microdialysis. J. neural Transm. (Gen. Sect.). 94:1993;91-102.
35. Maruyama W., Nakahara D., Ota M., Takahashi T., Takahashi A., Nagatsu T., Naoi M. N-Methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-sansolinol, in rat brains: in vivo microdialysis study. J. Neurochem. 59:1992;395-400.
36. McGeer P. L., Itagaki S., Akijama H. and McGeer E. G. (1989) Comparison of neuronal loss in Parkinson's disease and ageing. In Parkinsonism and Ageing (ed. Calne D. B.), pp. 25-34. Raven, New York.
37. 3H]dopamine into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem. Pharmac. 52:1996;29-34.
38. McNaught St P.K., Thull U., Carrapt P.-A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Toxicity to PC 12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 206:1996;37-40.
39. McNaught St P.K., Thull U., Carrapt P.-A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 5:1996;265-274.
40. Meltzer H.Y., Young M., Metz J., Fang V.S., Schyue P.M., Arora R.C. Extrapyramidal side-effects and increased serum prolactin following fluoxetine, a new antidepressant. J. neural Transm. 45:1979;165-175.
41. Mensil M., Testa B. and Jenner P. (1984) Xenobiotic metabolism by brain monooxygenases and other cerebral enzymes. In Advances in Drug Research (ed. Testa B.), Vol. 13, pp. 95-207. Academic, London.
42. Mera J. Serotonin and the extrapyramidal system - a neurological perspective. Human Psychopharmac. 11:1996;S95-S102.
43. Mortimer J.A., Webster D.D. Evidence for a quantitative association between EMG stretch responses and parkinsonian rigidity. Brain Res. 162:1979;169-173.
44. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci. Res. 29:1997;99-111.
45. Nagatsu T., Hirata Y. Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4-phenylpyridinium ion (MPP+) and structurally related compounds in vitro and in vivo. Eur. Neurol. 26:(Suppl. 1):1987;11-15.
46. Nagatsu T., Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci. Lett. 87:1988;178-182.
47. Naoi M., Dostert P., Yoshida M., Nagatsu T. N-Methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv. Neurol. 60:1993;212-217.
48. Naoi M., Matsuura S., Parvez H., Takahashi T., Hirata Y., Minami M., Nagatsu T. Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methylisoquinolinum ion by monoamine oxidase. J. Neurochem. 52:1989;653-655.
49. Naoi M., Matsuura S., Takahashi T., Nagatsu T. An N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin N-methylisoquinolinium ion. Biochem. biophys. Res. Commun. 161:1989;1213-1219.
50. Naoi M., Takahashi T., Parvez H., Kabeya R., Taguchi E., Yamaguchi K., Hirata Y., Minami M., Nagatsu T. N-Methylisoquinolinium ion as an inhibitor of tyrosine hydroxylase, aromatic L-amino acid decarboxylase and monoamine oxidase. Neurochem. Int. 15:1989;315-320.
51. Nimit Y., Schulze I., Cashaw J.L., Ruchirawat S., Davis V.E. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors. J. Neurosci. Res. 10:1983;175-189.
52. Niwa T., Takeda N., Kaneda N., Hashizume Y., Nagatsu T. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem. biophys. Res. Commun. 144:1987;1084-1089.
53. Niwa T., Tanaka N., Tatematsu A., Matsurra S., Yoshida M., Nagatsu T. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. J. Chromat. 452:1988;85-91.
54. Niwa T., Yoshizumi H., Tatematsu A., Matsuura S., Nagatsu T. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J. Chromat. 493:1989;347-352.
55. Niwa T., Yoshizumi H., Tatematsu A., Matsuura S., Yoshida M., Kawachi M., Naoi M., Nagatsu T. Endogenous synthesis of N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of N-methylisoquinolinium ion, in brains of primates with parkinsonism after system administration of 1,2,3,4-tetrahydroisoquinoline. J. Chromat. 533:1990;145-151.
56. Ogawa M., Araki M., Nagatsu I., Nagatsu T., Yoshida M. The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL/6J mice: immunohistochemical studies - tyrosine hydroxylase. Biogenic Amines. 6:1989;427-436.
57. Ohta S., Kohno M., Makino Y., Tachikawa O., Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed. Res. 8:1987;453-456.
58. Ossowska K., Lorenc-Koci E., Schulze G., Konieczny J., Wolfarth S., Bojarski M., Coper H. The role of reflex activity in the regulation of muscle tone in rats. Expl Physiol. 81:1996;211-223.
59. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, San Diego.
60. Rommelspacher H., Susilo R. Tetrahydroisoquinolines and β-carbolines: putative natural substances in plants and mammals. Prog. Drug Res. 29:1985;415-459.
61. Suzuki K., Mizuno Y., Yamaguchi Y., Nagatsu T., Yoshida M. Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain. J. neurol. Sci. 109:1992;219-223.
62. Suzuki K., Mizuno Y., Yoshida M. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline. Neurosci. Lett. 86:1988;105-108.
63. Tasaki Y., Makino Y., Ohta S., Hirobe M. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-treated mouse, prevents parkinsonian-like behavior abnormalities. J. Neurochem. 57:1991;1940-1943.
64. Testa B., Naylor R., Costall B., Jenner P., Marsden C.D. Does an endogenous methylpyridinium analogue cause Parkinson's disease? J. Pharm. Pharmac. 37:1985;679-680.
65. Wolfarth S., Konieczny J., Smialowska M., Schulze G., Ossowska K. Influence of 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway on the muscle tone and electromyographic activity measured during passive movements. Neuroscience. 74:1996;985-996.
66. Yoshida M., Niwa T., Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci. Lett. 119:1990;109-113.
67. Yoshida M., Ogawa M., Suzuki K., Nagatsu T. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. Adv. Neurol. 60:1993;207-211.